BPC-157 is not on the FDA's approved drug list, but the bulk active ingredient is permitted for compounding by a 503A pharmacy under Section 503A of the Federal Food, Drug, and Cosmetic Act
Toll-like receptor signaling in severe acute respiratory syndrome coronavirus 2-induced innate immune responses and the potential application value of toll-like receptor Immunomodulators in patients with coronavirus disease 2019
It is important to consult a dermatologist for a proper evaluation to determine the most suitable treatment response for your individual needs.
Scientists use it as a model compound to investigate strategies for improving the bioavailability, half-life, and tissue targeting of peptide therapeutics
For critical research, discard and reconstitute a fresh vial
2Galano A, Alvarez-Idaboy JR